Evidence map›Paper›PMID 40913654›Full record

ArticleCerebellum (London, England)2025

Trends in Invasive Interventions and Risk Factors for Early Critical Events in Multiple System Atrophy.

Monami Tarisawa, Masaaki Matsushima, Akihiko Kudo, Taichi Nomura, Hisashi Uwatoko, Shinichi Shirai, Ikuko Takahashi-Iwata, Ken Sakushima, Hiroaki Yaguchi, Isao Yokota and 12 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Cerebellum (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Monami TarisawaDepartment of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Masaaki MatsushimaDepartment of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Akihiko KudoDepartment of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Taichi NomuraDepartment of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Hisashi UwatokoDepartment of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Shinichi ShiraiDepartment of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Ikuko Takahashi-IwataDepartment of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Ken SakushimaDepartment of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Hiroaki YaguchiDepartment of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Isao YokotaDepartment of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Naoki NishimotoHokkaido University Hospital Clinical Research and Medical Innovation Center, Sapporo, Japan.
Jun SawadaDepartment of Cardiology, Nephrology, Pulmonology, and Neurology, Asahikawa Medical University, Asahikawa, Japan.
Takeshi MatsuokaDepartment of Neurology, Date Red Cross Hospital, Date, Japan.
Haruo UesugiDepartment of Neurology, Aizen Hospital, Sapporo, Japan.
Naoya MinamiDepartment of Neurology, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.
Kazuya SakoDepartment of Neurology, Nakamura Memorial Hospital, Sapporo, Japan.
Asako TakeiHokkaido Neurological Hospital, Sapporo, Japan.
Shin HisaharaDepartment of Neurology, Sapporo Medical University, Sapporo, Japan.
Yasuhiro KanataniDepartment of Clinical Pharmacology, Faculty of Medicine, Tokai University, Shibuya, Japan.
Akiko TamakoshiDepartment of Public Health, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Norihiro SatoHokkaido University Hospital Clinical Research and Medical Innovation Center, Sapporo, Japan.
Ichiro YabeDepartment of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. yabe@med.hokudai.ac.jp.

Funding

Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development 25ek0109797h0001Research Committee on the Medical Basis of Motor Ataxias, Health and Labour Sciences Research Grants, Ministry of Health, Labour, and Welfare, Japan. 23FC1010
6 · The paper itself

Abstract

Multiple system atrophy (MSA) is a progressive, adult-onset neurodegenerative disorder involving autonomic failure, cerebellar ataxia, and parkinsonism. Patients often require invasive interventions, such as gastrostomy or tracheostomy, and sudden death is common. This study aimed to elucidate patterns of invasive treatment and identify risk factors for tracheostomy or sudden death within 5 years of onset. In total, 214 patients diagnosed with MSA between November 2014 and October 2024 across 66 institutions in Hokkaido were enrolled in the Hokkaido Rare Disease Consortium for MSA (HoRC-MSA). Patients were grouped by clinical course and interventions. We analyzed use of invasive procedures, including enteral nutrition via gastrostomy, enterostomy, esophagostomy, nasogastric tube insertion, central venous nutrition, tracheostomy, and ventilator support. Multivariable analyses were performed to compare patients with and without early critical events, defined as tracheostomy or sudden death within 5 years of disease onset. Invasive procedures were performed in 63.1% of patients. Patients receiving enteral nutrition and tracheostomy had prolonged survival. Early events correlated with older onset age (mean, 65.9 years), orthostatic hypotension, stridor, and an elevated apnea-hypopnea index (median, 32.45). Patients with preserved activities of daily living (ADL) in the Unified MSA Rating Scale part Ⅳ also had an increased risk of early critical events. Autonomic dysfunction, sleep-disordered breathing, and vocal cord impairment predict key risk factors for early mortality in patients with MSA. Monitoring is necessary, regardless of preserved ADL. The impact of invasive interventions on quality of life should be further explored.

Indexed as

Multiple System AtrophyAgedAged, 80 and overDeath, SuddenEnteral NutritionFemaleGastrostomyHumansMaleMiddle AgedRisk FactorsTracheostomyCare levelHoRC-MSAmRSMSAMultiple system atrophyRisk factors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.